EARS - Auris Medical shares surge on data from Bentrio SARS-CoV-2 preclinical studies

Auris Medical shares climb ([[EARS]] +11.0%) after the company posted promising data from preclinical studies with Bentrio ((AM-301)) nasal spray in the prevention and mitigation of SARS-CoV-2.Data showed up to a 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controls.Viral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 hours post infection."These data provide strong evidence for Bentrio’s potential to help reduce the risk of SARS-CoV-2 infection of human mucosal cells when used preventatively and to decelerate its course when used shortly after its onset," CEO Thomas Meyer said.Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. Auris had announces that its affiliate Altamira Medica started preparations to conduct a study with its Bentrio for protection against airborne viruses and allergens in India, last month.

For further details see:

Auris Medical shares surge on data from Bentrio SARS-CoV-2 preclinical studies